Deliveries of this child-friendly antimalarial hit the 300 million mark. This child-friendly ACT is the first WHO prequalified child-friendly artemisinin-combination therapy (ACT).
Usage Rights & Restrictions
This media asset is free for editorial broadcast, print, online and radio use. It is restricted for other purposes. Copyright Mark Tuschman for Novartis AG.